Hypofractionated IMRT With Concurrent Chemotherapy in Muscle-invasive Bladder Cancer (HIRACUM)

NCT05453682 · clinicaltrials.gov ↗
NA
Phase
RECRUITING
Status
53
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Samsung Medical Center